Key Takeaways Akero Therapeutics shares traded near their all-time high as the drugmaker reported positive results in a study of its treatment for liver disease.The drug, known as EFX, helped reverse ...
The data appeared to slam the door on the idea that the advent of GLP-1 drugs would eliminate demand for drugs specifically ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback